Brokerages Anticipate Strongbridge Biopharma plc (NASDAQ:SBBP) Will Announce Quarterly Sales of $4.82 Million

Equities analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to announce $4.82 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Strongbridge Biopharma’s earnings. The lowest sales estimate is $4.70 million and the highest is $5.04 million. Strongbridge Biopharma posted sales of $4.30 million in the same quarter last year, which would indicate a positive year over year growth rate of 12.1%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, August 14th.

On average, analysts expect that Strongbridge Biopharma will report full-year sales of $20.06 million for the current financial year, with estimates ranging from $19.51 million to $20.96 million. For the next financial year, analysts expect that the firm will report sales of $31.23 million, with estimates ranging from $23.17 million to $48.34 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that that provide coverage for Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.09. Strongbridge Biopharma had a net margin of 227.79% and a return on equity of 79.31%. The company had revenue of $4.34 million during the quarter, compared to the consensus estimate of $4.69 million.



A number of research analysts recently issued reports on the stock. ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. TheStreet cut shares of YRC Worldwide from a “c” rating to a “d+” rating in a research note on Wednesday, May 15th. BidaskClub raised shares of Zumiez from a “hold” rating to a “buy” rating in a research note on Friday, April 26th. Zacks Investment Research raised shares of DLH from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, Oppenheimer set a $15.00 price objective on shares of Strongbridge Biopharma and gave the company a “buy” rating in a research note on Tuesday, March 26th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $13.07.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sphera Funds Management LTD. grew its stake in shares of Strongbridge Biopharma by 2.1% in the first quarter. Sphera Funds Management LTD. now owns 951,600 shares of the biotechnology company’s stock worth $4,739,000 after acquiring an additional 20,000 shares during the period. Private Advisors LLC bought a new stake in shares of Strongbridge Biopharma in the first quarter worth approximately $263,000. Vivo Capital LLC bought a new stake in shares of Strongbridge Biopharma in the first quarter worth approximately $4,552,000. Stonebridge Capital Management Inc. bought a new stake in shares of Strongbridge Biopharma in the first quarter worth approximately $55,000. Finally, Oppenheimer & Co. Inc. grew its stake in shares of Strongbridge Biopharma by 90.8% in the first quarter. Oppenheimer & Co. Inc. now owns 45,448 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 21,626 shares during the period. 50.12% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ SBBP traded up $0.05 during midday trading on Friday, reaching $2.92. The company’s stock had a trading volume of 65,053 shares, compared to its average volume of 312,443. Strongbridge Biopharma has a fifty-two week low of $2.76 and a fifty-two week high of $6.55. The stock’s 50 day moving average price is $3.09. The firm has a market cap of $155.47 million, a P/E ratio of 9.42 and a beta of 0.85.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

Featured Article: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.